Recent reports have indicated that small-molecule inhibitors of GSK3 have favorable metabolic effects in rodents, which exhibit some of the same metabolic effects as FGF21 administration, including improved glucose tolerance and prevention of diet-induced obesity [87–90]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.